Professor Brandi graduated, specialized in Internal Medicine and gained his PhD in Gastrointestinal cancers in Bologna University. He studied in Paris the chronomodulation for tumors and the relationship between microbiota and intestinal preneoplastic diseases. Reviewer several times for NEJM and many other journals. The scientific activity was initially dedicated to gastrointestinal carcinogenesis, while in the last decade he has been devoted to the clinical treatment and translational aspects of hepatobiliary cancers. He developed new treatments for hepatocellular carcinoma and he collected one of the largest series of biliary tract cancers in Europe. He is now working on new risk factors for cholangiocarcinoma as asbestos exposure.